For immediate release

16 October 2023

==> picture [596 x 198] intentionally omitted <==

CSL Capital Markets Day

CSL Limited (ASX:CSL; USOTC:CSLLY) will today hold its Capital Markets Day in Sydney, Australia.

Please find attached the presentation materials including a news release outlining the highlights of the day.

The briefing for investors and analysts will commence at 9:15am Australian Eastern Daylight Time.

The briefing will be webcast on the Company website at www.csl.com in the ‘Investors’ section under Presentations.

An archived copy of the webcast will be uploaded to the site later in the day.

Authorised for lodgement by:

Fiona Mead Company Secretary

For further information, please contact:

Investors: Bernard Ronchi Director, Investor Relations CSL Limited

P: +61 3 9389 3470 E: [email protected]

Stephen McKeon Director, Investor Relations CSL Limited P: +61 402 231 696 E: [email protected]

Media:

Jimmy Baker Communications CSL Limited P: +61 450 909 211 E: [email protected]

==> picture [122 x 108] intentionally omitted <==

CSL Limited Capital Markets Day

16 October, 2023

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL ) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange ( ASX ), available at www.asx.com.au This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

Legal Notice

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL’s ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

==> picture [42 x 6] intentionally omitted <==

----- Start of picture text -----

BUSINESS USE
----- End of picture text -----

==> picture [74 x 56] intentionally omitted <==

Agenda

9:00 – 9:15	Registration/Coffee
	Welcome	Mark Dehring
	Strategic Overview	Paul McKenzie
	CSL Seqirus	Ken Lim
	CSL Vifor	Hervé Gisserot
	Q&A
10:40 – 11:00	Break
	CSL Behring	Andy Schmeltz
	Q&A
12:30 – 13:30	Lunch
	Information & Digital	Mark Hill
	Finance & Sustainability	Joy Linton
	Research & Development	Bill Mezzanotte
	Q&A
	Concluding Remarks	Paul McKenzie
16:00 – 18:00	Refreshments – Marble Bar	CSL Team

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

Strategic Overview

Paul McKenzie CEO & Managing Director

==> picture [299 x 165] intentionally omitted <==

Leading Positions in Large, Growing Markets

==> picture [410 x 318] intentionally omitted <==

Global #1

in plasma protein therapies ~$38 billion industry

Global #2

in influenza vaccines ~$7 billion industry

Global #1 in iron ~$5 billion industry

==> picture [67 x 50] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

Positioned for Annual Double-Digit Earnings Growth

==> picture [77 x 77] intentionally omitted <==

Leading positions in high growth markets

Significant unmet need
Durable products driven by continued innovation and embedded know how

==> picture [74 x 74] intentionally omitted <==

Robust R&D Portfolio

Near-to-mid-term launches
Longer-term opportunities across platforms and therapeutic areas

==> picture [83 x 84] intentionally omitted <==

Yield & capacity expansion

Yield enhancement across plasma and manufacturing platforms
Investing in Ig and cell capacity

==> picture [78 x 78] intentionally omitted <==

Disciplined capital allocation for growth

R&D, CapEx and value-creating BD
• Partnerships across the value chain with leading companies

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [960 x 303] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Strategic Focus Areas

4 Attract, engage, 3 Invest in develop and new digital retain next technologies generation 2 Deliver our to drive leaders R&D pipeline business within our performance investment Realise COGS 1 envelope efficiencies, driving CSL Behring gross Drive top-line margin to growth across pre-pandemic our core levels and franchises beyond

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Management Team

==> picture [91 x 91] intentionally omitted <==

Andy Schmeltz

EVP, CSL Behring United States

==> picture [91 x 91] intentionally omitted <==

Joy Linton

Chief Financial Officer

Australia

==> picture [104 x 10] intentionally omitted <==

==> picture [91 x 91] intentionally omitted <==

Stephen Marlow

SVP and General Manager CSL Seqirus Australia

==> picture [91 x 90] intentionally omitted <==

Mark Hill

Chief Digital Information Officer United States

==> picture [91 x 91] intentionally omitted <==

Hervé Gisserot

SVP and General Manager CSL Vifor Switzerland

==> picture [91 x 90] intentionally omitted <==

Elizabeth Walker

EVP, Chief Human Resources Officer United States

==> picture [91 x 91] intentionally omitted <==

Bill Mezzanotte

EVP, Head Research & Development United States

==> picture [91 x 90] intentionally omitted <==

Kate Priestman

Chief Corporate & External Affairs Officer United Kingdom

==> picture [91 x 91] intentionally omitted <==

Ken Lim

EVP, Chief Strategy Officer Australia

==> picture [91 x 90] intentionally omitted <==

Greg Boss

EVP Legal and General Counsel United States

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

CSL Seqirus

Ken Lim Chief Strategy Officer, CSL

CSL Seqirus growth linked directly to differentiation strategy and core capabilities

==> picture [430 x 307] intentionally omitted <==

----- Start of picture text -----

CSL Seqirus historic growth
Seasonal Influenza Revenue (US$'M)
1,500
23% CAGR
1,000
500
-
FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23
Non-differentiated Differentiated
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [222 x 14] intentionally omitted <==

----- Start of picture text -----

Cornerstones for Success
----- End of picture text -----

==> picture [323 x 290] intentionally omitted <==

----- Start of picture text -----

Real World Differentiation
Evidence Strategy
Platform
Focus on Scaled
Innovation Manufacturing
Platforms
----- End of picture text -----

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 77] intentionally omitted <==

CSL Seqirus’s focus within its 4 strategic pillars drives its near and long-term success

==> picture [104 x 10] intentionally omitted <==

1. CONTINUED GROWTH IN INFLUENZA

==> picture [102 x 101] intentionally omitted <==

Opportunities in both new and existing markets to increase our global footprint

3. GROW BEYOND INFLUENZA

==> picture [119 x 98] intentionally omitted <==

Leverage core competence of respiratory vaccines

2. BROADEN OUR PANDEMIC BUSINESS

==> picture [63 x 71] intentionally omitted <==

Multi-pathogen pandemic capability

MANUFACTURING TECHNOLOGY

==> picture [92 x 92] intentionally omitted <==

Common technologies and yield investments to underpin our growth

Influenza still has significant unmet need, particularly in paediatric and older adult populations

Seasonal Influenza Burden

==> picture [320 x 263] intentionally omitted <==

----- Start of picture text -----

Deaths
12k – 52k
Hospitalisations
140-170k
Infections/Illness
9-41M
US Data: 2010-2020
----- End of picture text -----

Hospitalisation Rate Across Ages

==> picture [358 x 208] intentionally omitted <==

----- Start of picture text -----

70
Hosp. rate
60
50
40
30
20
10
0
<5 5-9 10-19 20-34 35-44 45-54 55-64 ≥65
Patient Age (years)
Rate
(per 10,000)
Hospitalisation
----- End of picture text -----

https://www.cdc.gov/flu/about/burden/ Accessed 8/8/23 Glezen WP, et al. Am Rev Respir Dis. 1987;136(3):550-555.

Putri, Wayan C.W.S. et al , Economic burden of seasonal influenza in the United States , Vaccine. 2018 Jun 22;36(27):3960-3966. Found at: https://pubmed.ncbi.nlm.nih.gov/29801998/ (Accessed September 2020

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

In influenza, Seqirus will grow the market through differentiation despite lower immunisation rates

==> picture [99 x 91] intentionally omitted <==

Historic Trend (US)

Expectations

Immunisation rates will return over time
Annualisation of COVID-19 boosters will reduce vaccine fatigue

==> picture [44 x 7] intentionally omitted <==

----- Start of picture text -----

COVID-19
----- End of picture text -----

CSL Seqirus growth will outpace the market through differentiation and advocacy efforts

==> picture [23 x 18] intentionally omitted <==

----- Start of picture text -----

2009
H1N1
----- End of picture text -----

Current Northern Hemisphere 2023/24 season to date (early, in progress)

On track to our pre-season commitments
Flawless supply season

Source: www.cdc.gov

Positioned to support in-season opportunities if they arise
N.B. we’re still early in the season

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL Seqirus focused on continuous innovation to reduce the burden of influenza

==> picture [99 x 91] intentionally omitted <==

==> picture [846 x 337] intentionally omitted <==

----- Start of picture text -----

Multiple
Differentiators
Differentiated
aH5N1c
QIVc
Undifferentiated
aQIVc
aTIV
aQIV
TIVe
sa-mRNA
aH5N1
QIVe Development Status: Development Status:
• QIVc: 6-month+ age extension • aQIVc: Phase III
• aQIV: Advanced Real-World Evidence • sa-mRNA flu: Pre-clinical
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

sa-mRNA technology differentiates

==> picture [94 x 91] intentionally omitted <==

==> picture [93 x 91] intentionally omitted <==

CSL Seqirus COVID-19 vaccine candidate

Differentiators of sa-mRNA Technology

Accelerating to market

Superior response to Omicron strain 1 as a booster in adults vs. approved booster (Phase III)

Licensing and collaboration agreement with Arcturus Therapeutics Inc.
• Finalising clinical programs
• Studying emerging variants
Regulatory submissions

2 Lower dose of mRNA

Global Launches Anticipated in 2024 - 2026

Duration of protection up 3 to 12 months

^ Links to online publications: https://www.medrxiv.org/content/10.1101/2023.07.13.23292597v1.full.pdf

==> picture [90 x 52] intentionally omitted <==

==> picture [90 x 51] intentionally omitted <==

==> picture [87 x 51] intentionally omitted <==

==> picture [92 x 51] intentionally omitted <==

==> picture [354 x 29] intentionally omitted <==

----- Start of picture text -----

Japan EU UK US
(via Meiji Seika)
----- End of picture text -----

https://ir.arcturusrx.com/news-releases/news-release-details/study-shows-novel-sa-mrnavaccines-offer-robust-broad-enduring

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

BUSINESS USE

New Flu Cell Culture facility in Australia to meet growing demand and pandemic protection

==> picture [84 x 320] intentionally omitted <==

==> picture [257 x 148] intentionally omitted <==

==> picture [237 x 148] intentionally omitted <==

==> picture [501 x 162] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [100 x 91] intentionally omitted <==

==> picture [95 x 91] intentionally omitted <==

==> picture [95 x 92] intentionally omitted <==

Project is on target for schedule and budget, with first production in Q1 2026 Cell culture manufacturing Anti-venom production Fill/Finish facilities

==> picture [67 x 50] intentionally omitted <==

Key Takeaways

CSL Seqirus is well positioned to continue its success in influenza:

==> picture [99 x 91] intentionally omitted <==

==> picture [102 x 92] intentionally omitted <==

==> picture [96 x 90] intentionally omitted <==

Capacity development well advanced to support aQIVc launch
Continuous innovation will enable CSL Seqirus to outpace market growth:
aQIVc setting new standard of care
sa-mRNA
sa-mRNA technology will differentiate CSL Seqirus vaccine in COVID-19

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

CSL Vifor

Hervé Gisserot General Manager, CSL Vifor

FY23 – a solid result with 11 months contribution[1]

==> picture [501 x 246] intentionally omitted <==

----- Start of picture text -----

Iron Therapy Nephrology
Dialysis Non-Dialysis
3
4
5
(Ex-US)
6
7
In Market products
----- End of picture text -----

==> picture [14 x 135] intentionally omitted <==

----- Start of picture text -----

In Market products
----- End of picture text -----

==> picture [68 x 31] intentionally omitted <==

~14% revenue growth[2] EPS accretive

Integration and cost synergies on track

==> picture [273 x 272] intentionally omitted <==

----- Start of picture text -----

FY23 Revenue By Therapy Group $m [1]
Total: $1,989m
3%, Other, $73
7%, Non Dialysis,
$136
51%,
Iron,
$1,009
39%,
Dialysis,
$771
----- End of picture text -----

1. Acquired 9[th] August 2022 ~approximately 11 months contribution

2. Eleven months FY22 pre CSL ownership and unaudited versus eleven months FY23 at constant currency

3. Licensed from F. Hoffman-La Roche AG., 4. Licensed from Pfizer Inc., 5. Licensed from ChemoCentryx, Inc., 6. Licensed from OPKO Health, Inc., 7. Licensed from Cara Therapeutics, Inc.

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL Vifor’s strategic framework will set the foundations to drive sustainable, profitable growth

==> picture [846 x 319] intentionally omitted <==

----- Start of picture text -----

Maximize Unlock revenue upside in Deliver successful launches
Ferinject® / Injectafer® Patient Blood Management and pipeline progress to
growth opportunities across CSL strengthen renal disease
position
Lean and efficient
operations to compete in the new environment
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Iron market: Unique conditions enabling us to drive long-term value

• Market development Continued market growth due to untapped potential

==> picture [33 x 33] intentionally omitted <==

Follow-on Competition

Limited number of follow-on products

==> picture [33 x 33] intentionally omitted <==

Innovation

No breakthrough innovation

==> picture [33 x 33] intentionally omitted <==

• Pricing dynamics Strong price competition ?

1. Kassebaum NJ. The Global Burden of Anaemia. Hematol Oncol Clin North Am. 2016;30(2):247-308

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Iron market: Unique conditions enabling us to drive long-term value

==> picture [103 x 40] intentionally omitted <==

Market Experience

• Market development Continued market growth due to untapped potential

Follow-on Competition

Limited number of follow on products

Innovation

No breakthrough innovation

• Pricing dynamics Strong price competition

Kassebaum NJ. The Global Burden of Anemia. Hematol Oncol Clin North Am. 2016;30(2):247-308

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Relentless focus on Ferinject[®] / Injectafer[®] growth

GROWTH

NEW COMPETITIVE LANDSCAPE

GEOGRAPHIC & MARKET EXPANSION

LCM & SCIENTIFIC EXCELLENCE

Tendering excellence
Non-clinical differentiation
Cost of goods improvement
Investment in RWE/RWD
New launch markets
New presentations / formulation
New indications
Maximizing value of •
partnerships Non-Biologic Complex Drug characterisation

SIGNIFICANT UNTAPPED MARKET POTENTIAL

RWE = Real World Evidence; RWD = Real World Data

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Patient Blood Management addresses a global health issue

Benefits For patients: • Improved outcomes • Increased safety

Health Problem Patient Blood Management Benefits Critical need to reduce whole blood Evidence-based approach to preserve For patients: transfusions patient’s own blood • Improved outcomes • Avoidable adverse outcomes • Three Pillars of PBM Increased safety • Wastage of scarce blood supply • Reduced risk of complications • Inefficient healthcare spend 01 Detect & manage and infections anaemia/iron deficiency For Health Systems: Due to: • Preserve blood for high-value usage 02 • Insufficient screening of iron deficiency Minimize blood loss • Decrease overall cost of care • Suboptimal intra-operative haemostasis • Improve Quality Indicators & KPIs 03 Optimize patient tolerance of post-op anaemia

==> picture [309 x 54] intentionally omitted <==

==> picture [261 x 49] intentionally omitted <==

==> picture [35 x 47] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Repeated Demonstrations of Patient & Health System Benefits when PBM is fully implemented

Benefits for health systems Decrease overall cost of care

Benefits for patients

Decrease overall cost of care Improved patient outcomes Length Mortality Infection AMI/stroke of stay Western Australia $18.1 m blood product Activity based cost Patient Blood cost savings over the savings between 28% 21% 31% 15% Management six-year study period ~ $80 m – $100 m Program[1] In-Hospital Length Adv. Events[] of stay Mayo Clinics[2] 22% reduction in Savings of $7 m in N=400,998 admissions Jan 2010 allogenic transfusions transfusion related 1.5% 15% costs through December 2017 at two Absolute risk integrated hospital campuses 49% reduction in RBC Savings of $2.1 m in Across 5 John transfusions orders blood acquisition Hopkins Hospitals[3] costs – ROI 400% University Hospital 40% reduction in Savings of $12.44 m* of Zurich[4] RBC transfusions in blood acquisition N=213,882 patients discharged costs over 4 years

==> picture [46 x 32] intentionally omitted <==

==> picture [46 x 31] intentionally omitted <==

N=213,882 patients discharged between 2012 and 2017 were included in this retrospective study

==> picture [67 x 50] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

Countries calling on PBM implementation leading to addressable market of $4-5B across range of specialties

==> picture [658 x 300] intentionally omitted <==

----- Start of picture text -----

World Health UK, Germany, 2021 Italy, 2016 Romania, 2018
Organization, 2021 2015: NICE guidelines PBM PBM guidelines PBM guidelines
2022: Preop anaemia Recommendations
Policy Brief on “The
management in
urgent need to Russia, 2022
CQUIN
implement PBM” Setting up MoH
working group to
develop PBM standard
Portugal,
2018: Pilot PBM project
in 8 hospitals China, 2022
2022: Decree requiring
PBM guidelines
PBM implementation
Africa, 2022
Mexico 2020 Dakar Declaration on
PBM guidelines the future of surgeries
in Africa
Spain, 2019 Australia, 2012 – 2019
PBM related KPIs intro- Guidelines, National
duced in certain regions Implementation
Strategy &
establishment of PBM
France, 2022
Advisory Committee
PBM guidelines
----- End of picture text -----

TOTAL addressable market[1] $4b to $5b[2] Estimates include EU5, US, Japan & Switzerland

1. Consisting therapeutic areas where we can address PBM in Pillar 1, Pillar 2 and Pillar 3. Areas of potential significant growth include Cardiothoracic Surgery, Orthopaedic Surgery, Major Vascular Surgery, Oncologic Surgery, Gynecologic & Obstetric Surgery, Transplant Surgery and possibly Trauma

2. Internal calculation. Potential PBM market size estimate based on number of addressable patients. Market sizing estimate assumes price erosion across all classes

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL is uniquely positioned in PBM to translate evidencebased medicine into evidence-based practice

Pre-surgery

During surgery

Post-surgery

Benefits of PBM

Diagnosing & treating iron-deficiency (anaemia)

Optimizing hemoglobin and erythropoiesis to avoid complication during and post surgery

Optimizing coagulation

Using factor concentrates to minimize need for allogenic blood products

Ensuring optimal & fast recovery

Managing anaemia & irondeficiency and post-operative bleeding & clot stability

==> picture [849 x 121] intentionally omitted <==

----- Start of picture text -----

1
CSL
Portfolio
----- End of picture text -----

1. Rights for PBM currently reside with Pfizer (licensor) – asset is part of VFMCRP (distribution limited to US dialysis and non-hospital market)

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Realising the market opportunity through integrated Go to Market operating model

==> picture [846 x 300] intentionally omitted <==

----- Start of picture text -----

RWD/RWE DIRECT ENGAGEMENT
Indication expansion & Shape Medical Practice
evidence generation through supporting
supporting PBM benefits policies
Build Influence
Scientific & Global &
Medical National
Leadership Policy Makers
Build Brand Assist Health
IMPLEMENTATION Position & Systems to DATA SERVICES &
Leadership Change
TOOLBOX PROTOCOLS
Compelling combined Support for Key Accounts
Behring & Vifor Portfolio to Implement PBM
Offering
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

BUSINESS USE

Strengthen renal disease position along the full spectrum of kidney disease

==> picture [846 x 335] intentionally omitted <==

----- Start of picture text -----

Prevent Kidney Chronic kidney Dialysis
Damage disease treatment Treatment
Preserving renal function Manage complications Manage complications
CKD Dialysis
Vadadustat [1]
(Ex-US) Managing transplant patients (including complications)
Sparsentan (EU, ANZ)
CSL964 Clazakizumab
Nephrology &
Multiple potential early- (GvHD prevention and (Ab-mediated rejection
Transplant TA stage assets treatment) and ESKD)
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

1. Currently in regulatory assessment by the U.S. FDA. Based on standard NDA resubmission review timelines, our partner Akebia Therapeutics expects a letter from the FDA acknowledging that the resubmission is complete, classifying the resubmission, and setting the PDUFA date at the end of October 2024.

==> picture [67 x 50] intentionally omitted <==

CSL Vifor key value catalysts will drive growth into the medium - long term

Near-term

Ferinject[®] reimbursement in China
Injectafer[®] Heart Failure US launch

Mid-term

Maximize strategic partnerships
PBM revenue upside
CSL 300
Long-term • Nephrology / Transplant pipeline
BD opportunities
Launches Kapruvia[® ] / Korsuva[®] , Tavneos[® ] & Sparsentan
Collaboration with Behring / Seqirus

Cost Synergies

Indications / Geographic expansion

R&D Opportunities

1. CUA = Calcific Uremic Arteriolopathy

2. PAD-ESKD = Peripheral Arterial Disease - End Stage Kidney Disease

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

Thank You / Questions

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

CSL Behring

Andy Schmeltz EVP, CSL Behring

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

PLASMA COLLECTION MANUFACTURING COMMERCIALISATION

==> picture [258 x 272] intentionally omitted <==

----- Start of picture text -----

DONOR.
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [297 x 272] intentionally omitted <==

----- Start of picture text -----

EMPLOYEE.
----- End of picture text -----

==> picture [136 x 133] intentionally omitted <==

==> picture [143 x 132] intentionally omitted <==

==> picture [141 x 133] intentionally omitted <==

==> picture [140 x 133] intentionally omitted <==

----- Start of picture text -----

PATIENT.
----- End of picture text -----

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

==> picture [884 x 324] intentionally omitted <==

----- Start of picture text -----

PLASMA COLLECTION MANUFACTURING COMMERCIALISATION
Grow
Plasma
Volume
Reduce
Plasma
Acquisition
Cost
EMPLOYEE. PATIENT.
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

PLASMA COLLECTION MANUFACTURING

COMMERCIALISATION

Grow Improve Plasma Ig and Volume Albumin Yield Reduce Plasma Acquisition Cost

==> picture [104 x 10] intentionally omitted <==

==> picture [136 x 133] intentionally omitted <==

==> picture [143 x 132] intentionally omitted <==

==> picture [141 x 133] intentionally omitted <==

==> picture [140 x 133] intentionally omitted <==

----- Start of picture text -----

PATIENT.
----- End of picture text -----

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth

Working together from Donor to Patient

PLASMA COLLECTION MANUFACTURING

COMMERCIALISATION

Grow Improve Plasma Ig and Volume Albumin Yield Reduce Plasma Acquisition Cost

Grow Key Medicines and Deliver Successful Launches

==> picture [68 x 108] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

PLASMA COLLECTION MANUFACTURING Grow Improve Plasma Ig and Volume Albumin Yield Reduce Plasma Acquisition Cost

COMMERCIALISATION Grow Key Medicines and Deliver Successful Launches

==> picture [68 x 108] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Snapshot of CSL Plasma’s Industry-Leading Collection Network

USA Germany Hungary
Key figures
Note: CSL Plasma also operates five centres in China. • 322 centres U.S. • 15 centres EU
•
39 12 centres opened in last year

==> picture [67 x 50] intentionally omitted <==

Global Plasma Collections Back on Track

-22% in FY21 | +24% in FY22 | +31% in FY23

FY21 FY22 FY23

==> picture [104 x 10] intentionally omitted <==

FY24

Source: Global Donor Management Systems

Leading the Way in Plasma Growth & Efficiency

==> picture [626 x 243] intentionally omitted <==

----- Start of picture text -----

Sourcing
Optimizing
Sufficient
Costs
Volume
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Multiple Levers to Support Collections Growth, Enabled by Digital Transformation

Optimize mix of qualified and new donors
Focus on donor and market segmentation
• Leverage personalized messaging and incentives RETENTION
FREQUENCY • Deliver best-in-class service
• Apply technology to guide fee setting
• Personalize experience via app

==> picture [214 x 14] intentionally omitted <==

----- Start of picture text -----

NEW LAPSED DONORS
----- End of picture text -----

Increase awareness across different media
Drive first-time donation with differentiated fees
• Digitize pre-registration and appointments

==> picture [104 x 10] intentionally omitted <==

==> picture [231 x 318] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Clear Path to Driving Cost Per Litre (CPL) Efficiencies

COVID disruption led to

However, we have turned the corner. Further CPL reductions over coming 4 years

1 - 3 YEARS

Higher donor fees to drive collections

Lower centre output and unfavourable cost absorption

Higher labor wage rates

==> picture [163 x 54] intentionally omitted <==

----- Start of picture text -----

01 Optimizing Fee
Structures
----- End of picture text -----

02 Focus on centre-level Labor Productivity
03 Continued Rollout of Rika Plasma Donation System

2 - 4 Years

==> picture [164 x 55] intentionally omitted <==

----- Start of picture text -----

Individualized 04
Nomogram
----- End of picture text -----

Improved Centre 05 Productivity and Cost Absorption

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

U.S. FDA Nomogram: Important Lever to Optimize Donations and Drive Plasma Yield

Collection Target: Weight & Hematocrit Launched in August 2023

Collection Target: Collection Target: Weight Weight, Hematocrit & Height Currently at most centres Anticipated launch in FY25, pending Terumo approval

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Benefits of Rika Plasma Donation System

Currently deployed in ~15 centres Roll-out schedule to be agreed with Terumo by December 2023

Donor Experience

Donor Safety

Fewer donor Improper deferrals; reduced collection volume donation time by due to employee ~30% error reduced by 85%

==> picture [93 x 92] intentionally omitted <==

==> picture [83 x 83] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

Sustainable Growth

Individualized Nomogram will improve average donation yield by ~10%

==> picture [102 x 102] intentionally omitted <==

Sustainability

Reduced biohazard disposable waste by 10-15%

==> picture [102 x 102] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Source: Global Donor Management System

Leading the Way in Plasma Growth & Efficiency

==> picture [226 x 232] intentionally omitted <==

----- Start of picture text -----

Sourcing
Sufficient
Volume
----- End of picture text -----

Digital Transformation
Rika Plasma Donation System
Nomogram A & I

==> picture [104 x 10] intentionally omitted <==

==> picture [221 x 221] intentionally omitted <==

----- Start of picture text -----

Optimizing
Costs
----- End of picture text -----

Enhanced Scheduling
Donor Fee Strategy
Fleet Optimization

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Improve Grow Key Plasma Ig and Medicines and Volume Albumin Deliver Successful Yield Launches Reduce Plasma Acquisition Cost

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Global Manufacturing Presence

==> picture [148 x 77] intentionally omitted <==

Bern, Broadmeadows, Switzerland Australia

Marburg, Germany

Core products: • Core products : • Core products: immunoglobulins & immunoglobulins & Human Albumin albumin albumin Behring, coagulation factors, critical care
Specialty products:
• • Specialty products: coagulation factors, Specialty products: anti-D-hyperimmune critical care, CSL312 hyperimmunes

==> picture [148 x 77] intentionally omitted <==

==> picture [147 x 77] intentionally omitted <==

Kankakee, Illinois, U.S.

Wuhan,

China

•
Core products: Core products: albumin, albumin, fractionation for immunoglobulins intermediate pastes

Specialty products: alpha1-proteinase inhibitor

Toll plasma services for Australia, New Zealand, Hong Kong, Malaysia & Taiwan

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Ig Yield Maximisation Strategy[1]

==> picture [472 x 334] intentionally omitted <==

1. Illustrative only

Subject to the success and timing of research and development activities and the decisions of regulatory authorities

==> picture [104 x 10] intentionally omitted <==

==> picture [243 x 171] intentionally omitted <==

Yield Improvements

Horizon 1

Process changes within regulatory filing
Data analytics and plasma allocation
Operational excellence

Horizon 2

Proprietary process improvements with some manufacturing retooling
Will require regulatory approval
• Targeted at litres producing Ig & Albumin only
Pilot work underway

==> picture [67 x 50] intentionally omitted <==

Operational Excellence

CSL Operating System Delivering Value Across Six Areas

==> picture [93 x 93] intentionally omitted <==

==> picture [94 x 93] intentionally omitted <==

==> picture [93 x 93] intentionally omitted <==

Productivity Service

Reliability

Engagement

Quality

Sustainability

Example Value

Reduction in cycle Increase level of On Reduction in time and increased Time In Full inventory capacity Delivery to markets

Increase in Reduction in More efficient schedule Repeat Deviations environmental adherence & write offs footprint

==> picture [67 x 50] intentionally omitted <==

CapEx Investments are Providing Capacity for Growth

CSL expects CapEx investment needs to reduce as major projects are now coming online

==> picture [919 x 414] intentionally omitted <==

----- Start of picture text -----

Annual CapEx Spend
New Capacity Online
30%
CSL Plasma Centers at Start of FY
Reduction in
IG Production CapEx Spend
COVID Dip
330
303
277
237
206
180
Marburg / Marburg
148 External Filling Fractionation
127
Broadmeadows Kankakee Bern Broadmeadows Broadmeadows
IG Bulk Fractionation Ig Bulk Albumin Bulk Fractionation
FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24
51
----- End of picture text -----

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Improve Grow Key Plasma Ig and Medicines and Volume Albumin Deliver Successful Yield Launches Reduce Plasma Acquisition Cost

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Strong CSL Behring Portfolio with Compelling Growth Drivers

==> picture [314 x 313] intentionally omitted <==

----- Start of picture text -----

FY23 Global Revenue
$9.3B/+12% [1,2]
50%
13%
7%
30%
IG Haemophilia HAE Others
----- End of picture text -----

Source:

1 FY23 Growth percentages shown at constant currency 2 Includes HPV royalties & Ig Hyperimmunes
3 Haemophilia includes Afstyla (Hem-A), Idelvion (Hem-B), Hemgenix (Hem-B), and other coagulation products.

==> picture [104 x 10] intentionally omitted <==

Immunoglobins (Ig)

PRIVIGEN[® ] has >1 Million patient years of therapy
HIZENTRA[®] , >10 years as worldwide market leader

Haemophilia[3]

IDELVION[® ] is the #1 Factor IX prescribed for prophylaxis
HEMGENIX[®] now launched in US

Hereditary Angioedema (HAE)

HAEGARDA[®] offers proven effectiveness of C1-inhibitor replacement
garadacimab to provide patients with the most efficacious and convenient LTP[*] therapy
Long term prophylaxis (LTP)

==> picture [67 x 50] intentionally omitted <==

Ig Usage Trends by Country Shows Significant Opportunity, Particularly Beyond US and Australia

==> picture [619 x 357] intentionally omitted <==

----- Start of picture text -----

Ig Consumption per Capita (gms/100K)
327
303
240
153
138
117
101
96
51
25
17
2
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

US, Australia and Canada are the leading countries for per capita Ig utilization
• Disease prevalence is consistent globally
• Clear opportunity to grow Ig subject to adequate supply

==> picture [67 x 50] intentionally omitted <==

Behring Ig Growth Opportunities Span Current and New Indications

7 Major Markets: Ig Market Volume by Indication (FY23)

==> picture [445 x 232] intentionally omitted <==

----- Start of picture text -----

IVIG SCIG
25%
73%
18%
4%
5%
5%
1%
19% 13%
29%
8%
----- End of picture text -----

Abbreviations: primary immunodeficiency (PID), secondary immune deficiency (SID), chronic immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG)

==> picture [104 x 10] intentionally omitted <==

Ig demand across core indications continues to grow: ‒ Ig replacement in PID, SID
‒ Ig as an immunomodulator in MG, CIDP, ITP
Multiple levers to sustain and expand leadership:
Real-world experience (RWE) and data generation
Launch of HIZENTRA pre-filled syringe offerings; 5ml, 10ml, 20ml, 50ml
‒ Exploring multiple additional indications including dermatomyositis (DM)

==> picture [86 x 58] intentionally omitted <==

==> picture [100 x 51] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

PRIVIGEN[®] and HIZENTRA[® ] : Compelling Offerings for Patients

Privigen[®]

==> picture [84 x 38] intentionally omitted <==

Hizentra[®]

==> picture [101 x 53] intentionally omitted <==

Standard of care IVIg with proven protection through reliable Ig restoration
- Market leading SCIg offering personalized treatment options to patients
15+ years in PID and ITP; 10+ years in CIDP
Demonstrated to improve motor function in CIDP:
Supported by PRIMA and PATH studies
1.1M patient years' experience across indications
Recommended for CIDP maintenance treatment in Peripheral Nerve Society (PNS) treatment guidelines[1]
Proven long-term protection with 5+ years of RWE in CIDP
Expanding into dermatomyositis (DM) as the first-and-only SCIg

Abbreviations: primary immunodeficiency (PI), chronic immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP)

1Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Eur J Neurol. 2021;1‐28. https://doi.org/10.1111/ene.14959.

==> picture [104 x 10] intentionally omitted <==

Behring Ig Portfolio to Outpace Market Growth

==> picture [405 x 333] intentionally omitted <==

----- Start of picture text -----

Projected Global Ig Market Volume [ ]
IVIg
30+%
share
FY23 FY28
SCIg
50+%
share
FY23 FY28
CSL Behring Rest of Market
Volume
Volume
----- End of picture text -----*

==> picture [104 x 10] intentionally omitted <==

==> picture [106 x 53] intentionally omitted <==

==> picture [88 x 37] intentionally omitted <==

Ig Market

==> picture [376 x 47] intentionally omitted <==

----- Start of picture text -----

5-Yr Vol
6-8% high single-digits
CAGR
----- End of picture text -----

Improving Ig market supply, strong underlying demand and improved diagnosis rates in PID
PRIVIGEN® (IVIg) and HIZENTRA® (SCIG) leadership in core indications while expanding to new areas of unmet need

==> picture [67 x 50] intentionally omitted <==

Haemophilia B

Disease Overview and Unmet Needs

==> picture [889 x 323] intentionally omitted <==

----- Start of picture text -----

Haemophilia B: A rare genetic bleeding disorder
It results from the ~38K people [2] ~20K people
absence or deficiency of Diagnosed with Treated with Factor
coagulation Factor IX Haemophilia B IX therapies
(FIX) [1] worldwide in 2021 [[2]]
•
Infusion Burden
Significant unmet
•
Durable Protection/ Stable FIX level
need persists despite •
Treatment options for patients with inhibitors
treatment advances •
Psychological and Social Impact
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

[1] National Bleeding Disorders Foundation [2] WFH Annual Survey 2021

PdFIX: Plasma-derived Factor IX; SArFIX: Short-acting recombinant Factor IX; LArFIX: Long-acting recombinant Factor IX

==> picture [67 x 50] intentionally omitted <==

IDELVION[®] and HEMGENIX[®] : Leading Through Innovation

==> picture [118 x 50] intentionally omitted <==

Idelvion

Well established standard of care
Provides highest factor levels for the longest period of time of any FIX replacement therapy
Offers personalized dosing options of up to 21days*
Safe and well tolerated with low incidence of adverse reactions

==> picture [154 x 34] intentionally omitted <==

Hemgenix[®]

Provides greater bleed protection vs prophy
63% patients reported zero bleeds in the 7 to 18-month period following infusion[[1}]
Eliminates routine prophylaxis
96% of people discontinued Factor IX prophylaxis and remained prophy-free[[1}]]
Sustains FIX levels projected to last 15+ years for majority of patients[[2]]
Safe and well tolerated with no treatment related SAE’s

*Where 21-day dosing is approved

==> picture [104 x 10] intentionally omitted <==

[1] HOPE-B trial [2] Jinesh Shah, factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of haemophilia B Hongseok Kim, Krupa Sivamurthy, Paul E. Monahan & Michael Fries (2023) Comprehensive analysis and prediction of long-term durability of , Current Medical Research and Opinion, 39:2, 227-237, DOI: 10.1080/03007995.2022.2133492Add durability modelling publication reference

==> picture [67 x 50] intentionally omitted <==

Behring Haemophilia B Portfolio to Outpace Market Growth

Projected Global Haemophilia B Market Revenue[*]

==> picture [357 x 138] intentionally omitted <==

35-40% share FY23 FY28 CSL Behring Rest of Market

==> picture [98 x 53] intentionally omitted <==

==> picture [376 x 155] intentionally omitted <==

----- Start of picture text -----

Haem B
Market
5-Yr Rev
4-6% high single-digits
CAGR
•
Haemophilia B market expected to grow
due the launch of advanced therapies
including gene therapy (GT)
----- End of picture text -----

Targeting the right patients for IDELVION® and HEMGENIX® will maximize success for CSL Haemophilia B portfolio

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Hereditary Angioedema (HAE)

Disease Overview and Unmet Needs

HAE results from missing or low levels of a protein called C1 esterase inhibitor (C1-INH) and can cause attacks of swelling, and often pain, in specific parts of the body.

Hereditary Angioedema: A rare genetic disorder

==> picture [31 x 39] intentionally omitted <==

==> picture [43 x 41] intentionally omitted <==

==> picture [60 x 16] intentionally omitted <==

----- Start of picture text -----

32%
51%
----- End of picture text -----

1/40,000-50,000 ~12K treated

50% Chance of passing it on to a child

50% increase in patients getting prophylaxis treatment between 2016 and 2023

patients in major markets

Laryngeal attacks that block the airway are potentially life threatening
Delayed diagnosis

Significant unmet • Treatment burden need persists despite • Lack of immediate acting prophylaxis treatments treatment advances

Psychological and Social Impact

Prophy patient share

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

HAEGARDA[®] and Garadacimab

Best in Class Prophylactic Efficacy

==> picture [109 x 53] intentionally omitted <==

Haegarda[®]

Addresses the root cause of HAE by replacing missing or dysfunctional C1-INH
Reduces the median frequency of HAE attacks by 95%*
Reduces the median frequency of rescue medication by >99%*
99% of US patient days were attack free for up to 2.7 yrs.+

*pivotal Phase 3 study results, + Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, COMPACT Investigators et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376:1131– 1140. doi: 10.1056/NEJMoa1613627.

==> picture [104 x 10] intentionally omitted <==

Garadacimab

First Factor XIIa therapy for HAE prevention working at the top of the cascade
One dose, once a month, in less than 15 seconds via prefilled pen
99% median reduction in attacks and rescue medication use per month vs placebo*
62% of patients (12 years of age +) were completely attack-free over 6-months*

==> picture [67 x 50] intentionally omitted <==

Behring HAE Portfolio to Outpace Market Growth

Projected Global HAE Market Revenue

==> picture [97 x 47] intentionally omitted <==

==> picture [430 x 184] intentionally omitted <==

----- Start of picture text -----

30+%
share
Revenue
----- End of picture text -----

==> picture [382 x 36] intentionally omitted <==

----- Start of picture text -----

FY23 FY24 FY25 FY26 FY27 FY28
CSL Behring All Others
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [122 x 28] intentionally omitted <==

==> picture [376 x 69] intentionally omitted <==

----- Start of picture text -----

garadacimab
HAE Market
5-Yr Rev
4-6% high single-digits
CAGR
----- End of picture text -----

Improved diagnosis rates and new prophylaxis therapies will drive market growth
CSL portfolio addresses the needs of patients with effective on-demand treatment (BERINERT[®] ) and prophylaxis therapy (HAEGARDA[®] )
HAEGARDA[®] /BERINERT[®] will continue to be preferred by patients who value natural C1 replacement for its strong efficacy, safety profile and track record
Garadacimab – potential best-in-class therapy for HAE prophylaxis

==> picture [67 x 50] intentionally omitted <==

Portfolio Enabled by Additional In-line Growth Drivers

FY23 Global Revenue $9.3B/+12%[1,2]

==> picture [429 x 292] intentionally omitted <==

----- Start of picture text -----

Hereditary Angioedema (HAE)
Haemophilia [3]
7%
13%
OTHER
30%
50%
Immunoglobins (Ig)
----- End of picture text -----

CSL sustained market leadership
• Leverage data generation and real-world
(11% in FY23) experience in expanded indications • Growth in treatment settings with high unmet needs
• Potential expanded indication in trauma
(10% in FY23) (Ph3)
Launch 4/5gram in US market
• Potential indications for acute graft-vs-
(24% in FY23) host disease

Source:

1 FY23 Growth percentages shown at constant currency 2 Includes HPV royalties & Ig Hyperimmunes
3 Haemophilia includes Afstyla (Hem-A), Idelvion (Hem-B), Hemgenix (Hem-B), and other coagulation products.

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth

Working together from Donor to Patient

PLASMA COLLECTION MANUFACTURING

COMMERCIALISATION

Grow Improve Plasma Ig and Volume Albumin Yield Reduce Plasma Acquisition Cost

Grow Key Medicines and Deliver Successful Launches

==> picture [68 x 108] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Improve Grow Key 1 Ig and Medicines and Albumin Deliver Successful Deploy Rika , Yield Launches Nomogram A/I, digital transformation and operational excellence

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

==> picture [884 x 324] intentionally omitted <==

----- Start of picture text -----

PLASMA COLLECTION MANUFACTURING COMMERCIALISATION
Grow Key
1 2
Medicines and
Deliver Successful
Deploy Rika, Deliver Horizon 1 yield
Launches
Nomogram A/I, improvements; advance
digital transformation Horizon 2
and operational
excellence
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

CSL Behring: Driving Sustainable, Profitable Growth

Working together from Donor to Patient

==> picture [884 x 324] intentionally omitted <==

----- Start of picture text -----

PLASMA COLLECTION MANUFACTURING COMMERCIALISATION
1 2 3
Deploy Rika , Deliver Horizon 1 yield Outpace market
Nomogram A/I , improvements ; advance growth in Ig ,
digital transformation Horizon 2 Haemophilia B and
and operational HAE
excellence
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

Thank You / Questions

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Information and Digital

Mark Hill

CDIO

We are selective in choosing digital opportunities with the

greatest potential to differentiate our business

==> picture [104 x 10] intentionally omitted <==

Our focus areas include:

Interactions with donors
The acceleration of science in pursuit of new therapies
Scaling the enterprise

Under these focus areas lies a massive injection of information and automation

Anchored in a mission to keep our company and its data safe and secure

==> picture [67 x 50] intentionally omitted <==

Pitch Deck

71 71

Value drivers for information and digital

==> picture [93 x 93] intentionally omitted <==

==> picture [93 x 92] intentionally omitted <==

==> picture [93 x 93] intentionally omitted <==

Differentiation Integration

Automation

Information

Cybersecurity

Making donations Unified and easier, while standard business ensuring uptime process workflows and resiliency of that drive our plasma centers. continuous productivity and Merging biological operational and computer leverage. science for pipeline growth.

Self-healing processes that reduce cycle time and improve the employee experience.

Making data the Maintaining connective tissue acceptable levels of risk of our enterprise by keeping technology ecosystem for current, employing real-time data cybersecurity flows. measures, establishing business continuity, and meeting regulatory requirements.

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Fusion of business and technology

Plasma: Making donations easier, creating a more positive donor experience, and bring in more donors

PLASMA

R&D

Enterprise

==> picture [454 x 348] intentionally omitted <==

----- Start of picture text -----

Digital Experience
Data
Artificial Intelligence
Innovation
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [328 x 335] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Fusion of business and technology

R&D: Merging biological and computer science for pipeline growth

Plasma

==> picture [135 x 21] intentionally omitted <==

----- Start of picture text -----

R&D
----- End of picture text -----

==> picture [135 x 21] intentionally omitted <==

----- Start of picture text -----

Enterprise
----- End of picture text -----

==> picture [946 x 402] intentionally omitted <==

----- Start of picture text -----

Scientific Insights
Accelerating the
pace of discovery.
Operational Excellence
Integrating our R&D
systems and processes
across businesses.
Data
The connective tissue across
R&D, driving science at scale
74
----- End of picture text -----

Fusion of business and technology

Enterprise: Capabilities for business performance and operational leverage

CSL Enterprise

Information

Real-time data flows that drive insights and seamless ecosystem connections.

Plasma

R&D

ENTERPRISE

==> picture [145 x 84] intentionally omitted <==

CSL

Automation

Self-healing processes that reduce cycle time and drive productivity at scale.

Behring B Seqirus S Vifor V Current State

==> picture [104 x 10] intentionally omitted <==

Integration

Unified and standard workflows to drive efficiencies and employee experience.

Target State

==> picture [67 x 50] intentionally omitted <==

Our Generative AI framework focuses on broad productivity, business outcomes and long-term value innovation

Focus Area 3: Breakthrough Innovation

==> picture [603 x 285] intentionally omitted <==

----- Start of picture text -----

Create game-changing outcomes and
differentiated assets (IP)
3
Focus Area 2: Select Use Cases
Prioritize a list of business cases
2
where we can drive value
Focus Area 1: Productivity Boom
Make as many people as
1
productive and effective as possible
# of users
Foundation
Policy, education,
Foundation
experimentation zone, catalyst
partners, governance
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

Illustrative use cases

3 Accelerate time to trial

3 Improve pharmacovigilance reporting

2 Improve patient experience

2 Improve tenders

2 Optimize inventory management 2 Improve the donor experience 1 Improve enterprise search 1 CSL GPT

==> picture [67 x 50] intentionally omitted <==

Cybersecurity remains the biggest risk in digital transformation

==> picture [54 x 55] intentionally omitted <==

Shifting regulatory requirements and geopolitical threats

==> picture [40 x 41] intentionally omitted <==

Generative AI risks:

Data leakage

==> picture [58 x 58] intentionally omitted <==

Generative AI

Hallucination (generating inaccurate responses)
Making cyber criminals more efficient and effective

==> picture [55 x 55] intentionally omitted <==

Cyber risk due to use of new technology/solutions and partners

Future capacity shortages (future phases of AI will require 100x more capacity than today)

Maintain an acceptable level of risk by keeping technology current, employing cybersecurity measures, establishing business continuity management and meeting regulatory requirements

==> picture [67 x 50] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

Takeaways

We see digitalization as a mechanism of scale , accelerating our business growth at less physical cost.

Fusion of business and technology are potential differentiators of our business in the donor experience, the speed of science, and enterprise leverage (extending our moat).

A massive infusion of automation and information are the new table stakes for keeping pace with industry and our ecosystem of partners.

Generative AI is a potential leapfrog opportunity , but also difficult to harness because the speed of innovation is faster than anything we have seen.

. Never forget our commitment to safety and security

. It is the most exciting time to be at the intersection of CSL and Digitalization

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

Finance and Sustainability

Joy Linton

CFO

Disciplined Management of Capital

Growing Cash Earnings

Maintain strong balance Returns to shareholders Re-invest in the Business Capital structure sheet • Dividend growth in line • R&D investment of 10 -11% • Annual Review • Net debt / EBITDA target with NPATA growth of revenue • Excess capital returned to ratio of less than 2.0x • Circa 40-45% payout • BD – selective investment shareholders
• Maintain investment in R&D assets • Steady improvement in
grade credit rating • Capex ROIC fuelled by double digit earnings growth ‐ Growth ~70% Partnering approach •
‐ Maintenance ~30% Long term valuation creation
• Capabilities, competencies, Adjacencies

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Capital Expenditure[1]

Key Points

==> picture [502 x 327] intentionally omitted <==

----- Start of picture text -----

Capex US$m % of Revenue
1,400 14%
~30% 13%
1,200
12%
1,000 11%
10%
800
9%
600
8%
7%
400
6%
200
5%
- 4%
Maint Growth % of Rev
----- End of picture text -----

1. Capital Expenditure for Property, Plant & Equipment - net of disposals

==> picture [104 x 10] intentionally omitted <==

Significant investment continued during COVID years providing capacity to meet future demand
Mid term capex needs reduced following natural run off of intensive program
Capacity enhanced through yield initiatives and accessing CMO’s for new capabilities - pushing out future capex needs

==> picture [67 x 50] intentionally omitted <==

Key Capital Projects - Completion Timeline

==> picture [849 x 385] intentionally omitted <==

----- Start of picture text -----

FY24 FY25 FY26 FY27 FY28 FY29 FY30
2023 2024 2025 2026 2027 2028 2029 2030
Rika Device Rollout
Technology
Veeva (Quality, PhV)
Broadmeadows: Mod 3 – Frac + CSL112
Base Frac
Future Base Frac – delayed need with Yield initiatives
Ig Yield Initiatives – Horizon 1
Ig Yield Initiatives – Horizon 2
Future IG Modules – delayed need with Yield & optimization initiatives
Bulk &
Zemaira 4/5g DP - TFS
Finishing
Broadmeadows Albumin Expansion 2
CSL 112 – Broadmeadows + Bern
Zemaira Bulk (+CSL964) Expansion
Plasma Centers (Continuous)
Other
Hemgenix – Second CMO
Seqirus Tullamarine Flu Cell Line 3
----- End of picture text -----

==> picture [67 x 50] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

ROIC Outlook

Earnings expansion fuelled by:

Differentiated product portfolios
Drive IG growth
New product launches
CSL Behring gross margin recovery

Steady improvement[1] in ROIC fuelled by double digit earnings growth

Continued growth in CSL Seqirus
CSL Vifor strategy realisation

Continues to exclude potential CSL112 upside

1.ROIC is expected to modestly soften in FY24, driven by the timing mismatch between the raising of funds to acquire Vifor Pharma and the payment of consideration

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Continued active management of inventory

==> picture [478 x 180] intentionally omitted <==

----- Start of picture text -----

8,000 CPL 200.0
7,500
180.0
7,000
6,500 160.0
6,000 140.0
5,500 Plasma Volumes
120.0
5,000
4,500 100.0
4,000
80.0
3,500
3,000 60.0
2017 2018 2019 2020 2021 2022 2023
----- End of picture text -----

==> picture [417 x 189] intentionally omitted <==

----- Start of picture text -----

$m Inventory % of revenue
6,000 100%
5,000 80%
4,000
60%
3,000
40%
2,000
20%
1,000
0 0%
2017 2018 2019 2020 2021 2022 2023
Finished Goods Work in Progress Raw Materials Inventory % Revenue
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

Increase in plasma volumes and CPL have accentuated the value of inventory

Key Challenges

Balancing inventory build versus fulfilling patient demand
IG on EMA short supply list until June 2024
Most ex-US markets require increased levels of safety stock
Plasma collection costs remain high, although downward trending
Inventory driven by higher CPL

Outlook

Balancing inventory build versus fulfilling patient demand remains
Pre pandemic, months of cover ~2.5x – 3.0x
FY25 target ~2.0x

==> picture [67 x 50] intentionally omitted <==

Strong Balance Sheet

Strong liquidity and competitive access to debt capital across multiple markets

US$m

==> picture [532 x 285] intentionally omitted <==

----- Start of picture text -----

2,000
1,800
1,600
1,400
1,200
1,000
800
600
400
200
-
Private Placement 144A QDI Bank Debt KfW Other Borrowings
FY24 FY25 FY26 FY27 FY28 FY29 FY30 FY31 FY32 FY33 FY35 FY38 FY42 FY52 FY62
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

Debt is strongly weighted towards long tenors at fixed rates

Net Debt / EBITDA 2.5x, expected to be ~2.0x by end FY24
Business focus for further debt reduction to ensure credit ratings maintained
70% of debt fixed with average tenor of 8.9 years
Weighted average cost of debt FY23 4.11% versus FY22 3.38%

Flexibility to continue access to deep and diverse capital pools

Successful US 144 A program creates funding optionality in largest liquidity market (average tenor 18 years)

Stable investment grade credit rating

S&P: A- (on negative watch)
Moody’s: A3

==> picture [67 x 50] intentionally omitted <==

As at 30 June 2023

==> picture [122 x 108] intentionally omitted <==

Sustainability

==> picture [960 x 90] intentionally omitted <==

Sustainability Pillars

ENVIRONMENT

Reduce Carbon Emissions
Reduce Waste & Emissions in the supply chain

(E)

delivering on our promises to preserve a healthier plant

Environmental considerations embedded in strategy

SOCIAL

Donor Experience

(S)

Patient & Public Health Leader

providing better care for brighter days ahead

Access to Our Therapies

SUSTAINABLE WORKFORCE

Employee Engagement

(W)

Diversity, Equity & Inclusion
• Giving

it’s the people behind our promise that makes us different

==> picture [486 x 380] intentionally omitted <==

----- Start of picture text -----

Ongoing
targeted
Diagnostic Ambitions Benefits
efforts
/ Baseline / Targets Roadmap Execution realization
In
In progress Completed Aligned Aligned In progress
progress
In progress Completed In progress In progress Next step Next steps
In progress Completed In progress In progress Next step Next Steps
----- End of picture text -----

GOVERNANCE (G)

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Key Sustainability Indicators and Highlights

Environment

SBTi 1.5⁰[C]

100%

Renewable Electricity (RE) across all our major European manufacturing sites, with Australia to follow in Jan 2025. Evaluating promising RE options for our US based manufacturing sites.

Committed to be aligned with SBTi 1.5 ⁰C Submitted to SBTi for validation in 2023

5-star Green Star

190+

by Design rating given to new Melbourne, AUS Headquarter from the Green Building Council of Australia; representing excellence in sustainable building practices.

Suppliers engaged setting their own SBTi aligned targets (Scope 3)

==> picture [104 x 10] intentionally omitted <==

Social

94%

475

of plasma donors are regulatory inspections of willing to donate again and our manufacturing 91% are willing to refer a facilities and plasma friend to donate plasma at collection centers with no their CSL plasma center impact to licenses

Approved Reflect RAP

>US $1B CSL’s Reflect investment into research Action Plan and development US $13.7M supporting product access across the world Data as at 30 June 2023

CSL’s Reflect Reconciliation Action Plan launched in September 2023

Workforce

59%

Female Employees

==> picture [37 x 43] intentionally omitted <==

==> picture [156 x 211] intentionally omitted <==

----- Start of picture text -----

44%
Female representation
at board level
45%
of people managers
are women
Data as at 30 June 2023
----- End of picture text -----

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

Research & Development

Bill Mezzanotte Executive Vice President, Head of R&D

==> picture [155 x 33] intentionally omitted <==

==> picture [151 x 33] intentionally omitted <==

==> picture [146 x 26] intentionally omitted <==

ONE CSL R&D

==> picture [104 x 10] intentionally omitted <==

==> picture [116 x 26] intentionally omitted <==

==> picture [243 x 419] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Focus Through Our Therapeutic Areas and Platforms

==> picture [852 x 170] intentionally omitted <==

New: Nephrology

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Enhancing R&D’s Global Capabilities

==> picture [236 x 89] intentionally omitted <==

Melbourne, Australia

New Global Headquarters and Centre for R&D in Melbourne Biomedical Precinct
~40,000 m2 including:
18 stories for >850 employees
9 levels of world-class laboratories & facilities
Australia’s first-of-its-kind biotech incubator

==> picture [89 x 29] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [239 x 89] intentionally omitted <==

Marburg, Germany

New R&D Campus
• ~40,000 m2 for >500 R&D employees including:
7,400m2 laboratory space
10,300m2 working space
state-of-the-art vivarium
Collaborative laboratory space

==> picture [236 x 89] intentionally omitted <==

Waltham, USA

R&D centre supporting sa-mRNA technology for seasonal & pandemic influenza vaccines
~13,000 m2 including:
5,000m2 laboratory space
Biosafety level 3 laboratory (BSL-3)
Collaborative laboratory space

==> picture [67 x 50] intentionally omitted <==

CSL R&D Portfolio – FY23

PhaseI

PhaseII

Phase III

Anumigilimab (CSL324) HIZENTRA[®] HIZENTRA[®] INJECTAFER[®] Anti-G-CSFR mAb(HS) (SSc) (DM) (Ferric carboxymaltose) (HF-ID) CSL730 CSL301 Garadacimab rFc Multimer α2AP mAb (PE) Anti-FXIIa mAb(HAE) FILSPARI  ( Sparsentan) Dual ETA & AT1 antagonist CSL889 Garadacimab KCENTRA[®] (FSGS) Hemopexin(SCD) Anti-FXIIa mAb(ILD/IPF) 4F-PCC (Trauma) FILSPARI  ( Sparsentan) CSL787 Clazakizumab CSL1 1 2 Dual ETA & AT1 antagonist (IgAN) NebulisedIg Anti-IL-6 mAb(ESKD) apoA-I(AMI) Trabikibart (CSL311) SQ036 (aQIVc) Clazakizumab SNF472 Anti-Beta Common mAb Adjuvanted Cell-based Anti-IL-6 mAb(ca-AbMR) Calcification inhibitor Quadrivalent Influenza (CUA-ESKD) INS-3001 Vaccine CSL964 Calcification inhibitor Alpha-1Antitrypsin SNF472 (PAD, AVS) Mavrilimumab (Treatment of aGvHD) Calcification inhibitor Anti-GM-CSFR mAb (PAD-ESKD) (GCA, COVID) CSL964 Alpha 1Antitrypsin ARCT154 Eblasakimab (CSL334) (Prevention of aGvHD) sa-mRNA Vaccine Anti-IL-13R mAb(AD) (COVID) VAMIFEPORT Ferroportin inhibitor (SCD)

Immunology Haematology Respiratory Cardiovascular & Metabolic Transplant Vaccines CSL Vifor Outlicensed Programs Partnered Projects

==> picture [104 x 10] intentionally omitted <==

Registration/Post-Registration

HAEGARDA[®] (HAE)

FLUAD[®] Quadrivalent Adjuvanted Egg-based Influenza Vaccine

HIZENTRA[®] (SCIg) 20% Liquid PRIVIGEN[®] (IVIg) 10% Liquid AFSTYLA[®] rFVIII (HaemA)

FLUCELVAX[®] Quadrivalent Cell-based Influenza Vaccine

PANVAX[®] Egg-based Influenza Vaccine FERINJECT[®] Ferric carboxymaltose (ID)

IDELVION[®] Ferric carboxymaltose rFIX-FP (HaemB) (ID) HEMGENIX[®] KORSUVA[® ] /KAPRUVIA[®] (Haem B) KOR. agonist (CKD-aP) ZEMAIRA[®] /RESPREEZA[®] Alpha-1 Antitrypsin RAYALDEE[®] Oral ext. release calcifediol FOCLIVIA[®] /AFLUNOV[®] (SHPT) Adjuvanted Egg-based Influenza A (H5N1) Vaccine TAVNEOS[®] Oral C5a receptor inhibitor AUDENZ™ (AAV) Adjuvanted Cell-based Monovalent Influenza A VELPHORO[[®]] (H5N1) Vaccine

VELPHORO[[®]] (H5N1) Vaccine Sucroferric oxyhydroxide AFLURIA[®] QUAD (Serum P control in CKD) Egg-based Influenza Vaccine VELTASSA[®] FLUAD[[®]] Trivalent Oral potassium binder Adjuvanted Egg-based (HK)

FLUAD[[®]] Trivalent Adjuvanted Egg-based Influenza Vaccine

==> picture [67 x 50] intentionally omitted <==

CSL R&D Portfolio – FY23 Transitions

Phase I

PhaseII

Phase III

Registration/Post-Registration

HAEGARDA[[®]][[/]] BERINERT FLUAD[[®]] Quadrivalent (HAE) Adjuvanted Egg-based Influenza Vaccine

Anumigilimab (CSL324) CSL301 HIZENTRA[®] INJECTAFER[®] HAEGARDA[[®]][[/]] BERINERT FLUAD[[®]] Quadrivalent Anti-G-CSFR mAb(HS) α2AP mAb (PE) (DM) (Ferric carboxymaltose) (HAE) Adjuvanted Egg-based (HF-ID) Influenza Vaccine CSL730 Garadacimab Garadacimab HIZENTRA[®] rFcMultimer Anti-FXIIa mAb(ILD/IPF) Anti-FXIIa mAb(HAE) FILSPARI  ( Sparsentan) (SCIg) 20% Liquid FLUCELVAX[®] Quadrivalent CSL889 Dual ETA & AT1 antagonist Cell-based Influenza Vaccine Hemopexin(SCD) Clazakizumab KCENTRA[®] (FSGS) PRIVIGEN[®] (IVIg) 10% Liquid CSL787 Anti-IL-6 mAb(ESKD) 4F-PCC (Trauma) FILSPARI  ( Sparsentan) Egg-based Influenza Vaccine PANVAX[®] NebulisedIg HIZENTRA[®] CSL1 1 2 Dual ETA & AT1 antagonist AFSTYLA[®] (IgAN) rFVIII (HaemA) (SSc) apoA-I(AMI) Trabikibart (CSL311) FERINJECT[®] Anti-Beta Common mAb SQ036 (aQIVc) Clazakizumab SNF472 IDELVION[®] Ferric carboxymaltose Adjuvanted Cell-based Anti-IL-6 mAb(ca-AbMR) Calcification inhibitor rFIX-FP (HaemB) (ID) Anumigilimab (CSL324) Quadrivalent Influenza (CUA-ESKD) Anti-G-CSFR mAb Vaccine CSL964 HEMGENIX[®] KORSUVA[® ] /KAPRUVIA[®] (CAP ARDS) Alpha-1Antitrypsin SNF472 (Haem B) KOR. agonist CSL040 Mavrilimumab (Treatment of aGvHD) Calcification inhibitor (CKD-aP) Complement R1 Inhibitor Anti-GM-CSFR mAb (PAD-ESKD) ZEMAIRA[®] /RESPREEZA[®] (GCA, COVID) CSL964 Alpha-1 Antitrypsin RAYALDEE[®] SQ009 Alpha 1Antitrypsin ARCT154 Oral ext. release calcifediol Cell-based Influenza (H2N3) Vaccine Eblasakimab Anti-IL-13R mAb(AD) (CSL334) (Prevention of aGvHD) sa-mRNA Vaccine (COVID) FOCLIVIA Adjuvanted Egg-based[®] /AFLUNOV[®] (SHPT) Influenza A (H5N1) Vaccine SQ012 TAVNEOS[®] sa-mRNA Influenza (H5N1) VAMIFEPORT Oral C5a receptor inhibitor Vaccine Ferroportin inhibitor AUDENZ™ (AAV) (SCD) Adjuvanted Cell-based ARCT2138 Monovalent Influenza A VELPHORO[®] sa-mRNA Quadrivalent (H5N1) Vaccine Influenza Vaccine Sucroferric oxyhydroxide AFLURIA[®] QUAD (Serum P control in CKD) LASN01 Egg-based Influenza Vaccine Anti-IL-11R mAb VELTASSA[®] (IPF,TED) FLUAD[®] Trivalent Oral potassium binder INS-3001 Adjuvanted Egg-based (HK) Calcification inhibitor Influenza Vaccine (PAD, AVS) C1 Inhibitor Immunology Haematology Respiratory Cardiovascular & Metabolic Transplant (AIS) Vaccines CSL Vifor Outlicensed Programs Partnered Projects

CSL R&D Portfolio – FY24

PhaseI

PhaseII

Phase III

Registration/Post-Registration

CSL889 Anumigilimab (CSL324) HIZENTRA[®] HAEGARDA[®] FILSPARI  ( Sparsentan) AUDENZ™ Hemopexin(SCD) Anti-G-CSFR mAb(HS) (DM) (HAE) Dual ETA & AT1 antagonist Adjuvanted Cell-based (IgAN) Monovalent Influenza A Anumigilimab (CSL324) VAMIFEPORT KCENTRA[®] HIZENTRA[®] (H5N1) Vaccine Anti-G-CSFR mAb Ferroportin inhibitor 4F-PCC (Trauma) (SCIg) 20% Liquid KORSUVA[® ] /KAPRUVIA[®] FOCLIVIA[®] /AFLUNOV[®] (CAP ARDS) (SCD) KOR. agonist Adjuvanted Egg-based CSL1 1 2 PRIVIGEN[®] (CKD-aP) Influenza A (H5N1) Vaccine Trabikibart (CSL311) CSL301 apoA-I(AMI) (IVIg) 10% Liquid Anti-Beta Common mAb α2AP mAb (PE) RAYALDEE[®] FLUAD[®] Trivalent SNF472 Garadacimab Oral ext. release calcifediol Adjuvanted Egg-based CSL787 Garadacimab Calcification inhibitor Anti-FXIIa mAb(HAE) (SHPT) Influenza Vaccine NebulisedIg Anti-FXIIa mAb(ILD/IPF) (CUA-ESKD) AFSTYLA[®] TAVNEOS[®] FLUAD[®] Quadrivalent C1 Inhibitor Clazakizumab FILSPARI  ( Sparsentan) rFVIII (HaemA) Oral C5a receptor inhibitor Adjuvanted Egg-basedInfluenza Vaccine (AIS) Dual ETA & AT1 antagonist (AAV) Anti-IL-6 mAb(ESKD) (FSGS) IDELVION[®] FLUCELVAX[®] CSL040 Mavrilimumab rFIX-FP (HaemB) VELPHORO[®] Quadrivalent Complement R1 Inhibitor Clazakizumab Sucroferric oxyhydroxide Cell-based Influenza Vaccine Anti-GM-CSFR mAb Anti-IL-6 mAb(ca-AbMR) HEMGENIX[®] (Serum P control in CKD) SQ009 (GCA, COVID) (Haem B) ARCT154 Cell-based Influenza CSL964 VELTASSA[®] sa-mRNA Vaccine (H2N3) Vaccine Eblasakimab (CSL334) Alpha 1Antitrypsin ZEMAIRA[®] /RESPREEZA[®] Oral potassium binder (COVID) Anti-IL-13R mAb(AD) (Treatment of aGvHD) Alpha 1 Antitrypsin (HK) SQ012 sa-mRNA Influenza INJECTAFER[®] (H5N1) Vaccine CSL964 (Ferric carboxymaltose) Alpha 1Antitrypsin (HF-ID) (Prevention of aGvHD) ARCT2138 sa-mRNA Quadrivalent Influenza Vaccine SQ036 (aQIVc)

SQ036 (aQIVc) Adjuvanted Cell-based Quadrivalent Influenza Vaccine

LASN01 Anti-IL-11R mAb (IPF,TED)

==> picture [104 x 10] intentionally omitted <==

Immunology	Haematology	Respiratory	Cardiovascular & Metabolic	Nephrology & Transplant
Vaccines	CSL Vifor	Outlicensed Programs	Partnered Projects

==> picture [67 x 50] intentionally omitted <==

R&D Focus

Investments Coming to Fruition

==> picture [69 x 70] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

Deliver a Promising Portfolio

Strengthen our Core Platforms

CSL112
Flu Cell Culture yield
Garadacimab HAE
Iron evidence &
Clazakizumab ca-AbMR
optimisation
KCENTRA[®] Trauma
Patient Blood Management
CSL964 aGvHD
Sparsentan
Ig yield
sa-mRNA for COVID (near term) & Influenza (medium term)
aQIVc

==> picture [104 x 10] intentionally omitted <==

==> picture [243 x 419] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Ig Yield Horizon 2

==> picture [753 x 415] intentionally omitted <==

----- Start of picture text -----

Horizon 2
Manufacturing
Enhancement
Product
Comparability
Performance
Assessment
Iterative Health Authority
Engagement
LABORATORY SCALE PILOT SCALE STABILITY FILING
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Significant Target Launch Dates

==> picture [792 x 288] intentionally omitted <==

----- Start of picture text -----

FY23 FY24 - FY27
HEMGENIX [®] HIZENTRA [®] VELPHORO [® ] CSL964 AAT
Etranacogene SCIg 20% Liquid (DM) Sucroferric oxyhydroxide (aGvHD Treatment)
dezaparvovec (Haem B) (Serum P control in CKD)
China
BERINERT [® ] SC HIZENTRA [®] KORSUVA [® ] /KAPRUVIA [®] CSL964 AAT
C1 Esterase Inhibitor SCIg 20% Liquid (50mL KORAgonist (CKD-aP) (aGvHD Prevention)
(HAE) Japan PFS)
INJECTAFER [® ] Garadacimab Clazakizumab SQ036 (aQIVc)
Ferric carboxymaltose Anti-FXIIa (HAE) Anti-IL-6 (ca-AbMR) Adjuvanted Cell-based
(HF-ID) US Quadrivalent Influenza Vaccine
FERINJECT [® ] CSL112 Sparsentan ARCT154
Ferric carboxymaltose ApoA-1 (AMI) Dual ETA & AT1 antagonist sa-mRNA Vaccine
(ID) China (IgAN) EU (COVID)
----- End of picture text -----

Immunology	Haematology	Cardiovascular & Metabolic	Nephrology & Transplant
Vaccines	CSL Vifor	Outlicensed Programs	Partnered Project

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

Forward-Looking Portfolio Highlights – FY24

==> picture [43 x 41] intentionally omitted <==

Cardiovascular

& Metabolic

==> picture [43 x 41] intentionally omitted <==

Haematology

==> picture [43 x 41] intentionally omitted <==

Respiratory

CSL112 (ApoA ~~-~~ 1) AMI Phase III top line results
Clazakizumab (ESKD)
Phase IIb complete
Phase III first patient in

==> picture [43 x 41] intentionally omitted <==

Immunology

Garadacimab (Anti-FXIIa) HAE • EU, US & JP submissions
HIZENTRA[®] DM Phase III enrolment complete
HIZENTRA[®] PFS 50mL
US Launch
EU submission
Anumigilimab (Anti-G-CSFR) HS Phase II study first patient in

==> picture [79 x 19] intentionally omitted <==

Horizon 2

Ongoing pre ~~-~~ clinical studies with pilot plant materials
IDELVION[® ] China Phase III first patient in
Vamifeport (SCD) last patient out
CSL889 (Hemopexin) SCD Phase I top line results

==> picture [43 x 41] intentionally omitted <==

Nephrology & Transplant

Clazakizumab (Anti ~~-~~ IL ~~-~~ 6) ca ~~-~~ AbMR Phase III study 200 patients enrolled
CSL964 (Treatment of aGvHD) Phase III top line results
FILSPARI  (sparsentan) (IgAN) EU approval
VELPHORO[®] China launch
VELTASSA[® ]
AU Launch
US & EU paediatric approval
Trabikibart (Anti ~~-~~ Beta Common) ASTH Phase I study complete
Garadacimab (Anti ~~-~~ FXIIa) IPF/ILD Phase IIa study complete
CSL787 (Neb Ig) Phase I study complete

==> picture [42 x 42] intentionally omitted <==

Vaccines

aQIVc (Adjuvanted Cell-based Quadrivalent Influenza Vaccine) Phase III study 50yr+ first patient in
• ARCT154 sa-mRNA (COVID)
- JP approval
- US & EU submissions
SQ012 sa-mRNA (H5N1) Flu Phase I first patient in
ARCT2138 sa-mRNA Quad Flu Phase I first patient in
Ongoing HA engagement

==> picture [104 x 10] intentionally omitted <==

Abbreviations: ca-AbMR - Chronic Active Antibody-Mediated Rejection; ESKD – End Stage Kidney Disease; EU – Europe; HA – Health Authority; HAE – Hereditary Angioedema; IgAN - IgA Nephropathy; ILD – Interstitial Lung Disease; IPF - Idiopathic Pulmonary Fibrosis; JP – Japan; Neb Ig - Nebulised Ig; PFS – Pre-Filled Syringe; samRNA – Self-Amplifying messenger RNA; RNA – Ribonucleic Acid; SCD – Sickle Cell Disease; US – United States

==> picture [67 x 50] intentionally omitted <==

==> picture [122 x 108] intentionally omitted <==

Thank You / Questions

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

100

==> picture [122 x 108] intentionally omitted <==

Concluding Remarks

Paul McKenzie CEO & Managing Director

Financial Outlook

FY24 Guidance

FY24 Guidance
Revenue	Growth of 9-11% @CC_RE-AFFIRMED_
NPATA	Growth of 13-17% @CC
	$2.9 - $3.0 billion @CC_RE-AFFIRMED_
Capex	Down 30%
Operating efficiency	G&A ~5% of revenue
Balance sheet	Circa 2x net debt / EBITDA

Outlook

Outlook
CSL Behring gross margin	Recovering to pre-covid margin in 3-5 years
ROIC	Steady improvement1 in ROIC fuelled by double digit earnings
	growth

==> picture [104 x 10] intentionally omitted <==

1.ROIC is expected to modestly soften in FY24, driven by the timing mismatch between the raising of funds to acquire Vifor Pharma and the payment of consideration

==> picture [67 x 50] intentionally omitted <==

102

Strategic Positioning

Growing global markets with significant unmet patient need
Best in class, durable products driven by continued innovation
Scaled manufacturing platforms underpinned by embedded know how

Near Term / Recent Activity

Near Term / Recent Activity Market Opportunities Outpacing industry growth Industry volume growth 6-8% p.a. Ig yield initiatives underway (Horizon 1 & 2) US/Canada/Aust Ig consumption 2-3x that of Immunoglobulins EU Hizentra for dermatomyositis Disease prevalence consistent globally New technologies aQIVc and sa-mRNA Recovery in vaccination rates Vaccines COVID vaccine – preparation for global licensure Ongoing portfolio differentiation Flu cell culture yield improvement Heart Failure label expansion for Injectafer in US 30% of population has iron deficiency; of which Iron 50% have iron deficiency anaemia Approval of Ferinject in China Patient Blood Management strategy

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

103

R&D Programs – Near Term Milestones

	Opportunity	FY24
Garadacimab (HAE)	Potentially best in class treatment option for HAE patients	EU, US & JP submissions
Clazakizumab (ca-AbMR)	AbMR is leading cause of transplant failure	Phase III study - 200 pts enrolled
KCENTRA® (Trauma)	Trauma is leading cause of morbidity &	Phase III study tracking towards 2000
	mortality in US	patients enrolled for interim analysis
CSL112 ApoA-1 (AMI)	Potentially transform treatment of AMI
	patients at high-risk of recurrent	Phase III top line results
	cardiovascular events
Sparsentan (IgAN)	IgAN is major cause of kidney failure	EU approval
aQIVc	Potential to set standard of care for patients 50yr+	Phase III study 50yr+ first patient in
sa-mRNA	Efficacy, tolerability, durability & flexibility	Japan approval (COVID)
	for flu and beyond	Phase I study first patient in (Flu)
Ig Yield initiatives	Horizon 1	Implementation of first improvements
	Horizon 2	Ongoing pilot plant activities

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

104

Positioned for Annual Double-Digit Earnings Growth

==> picture [77 x 77] intentionally omitted <==

Leading positions in high growth markets

Significant unmet need
Durable products driven by continued innovation and embedded know how

==> picture [74 x 74] intentionally omitted <==

Robust R&D Portfolio

Near-to-mid-term launches
Longer-term opportunities across platforms and therapeutic areas

==> picture [83 x 84] intentionally omitted <==

Yield & capacity expansion

Yield enhancement across plasma and manufacturing platforms
Investing in Ig and cell capacity

==> picture [78 x 77] intentionally omitted <==

Disciplined capital allocation for growth

R&D, CapEx and value-creating BD
• Partnerships across the value chain with leading companies

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

105

==> picture [101 x 89] intentionally omitted <==

CSL Contacts

Mark Dehring VP Investor Relations  +61 3 9389 3407 [email protected]

Bernard Ronchi Investor Relations  +61 3 9389 3470 [email protected]

Stephen McKeon Investor Relations  +61 3 9389 6798 [email protected]

NEWS RELEASE

For immediate release

16 October 2023

==> picture [141 x 42] intentionally omitted <==

CSL well-positioned to deliver sustainable, profitable growth

SYDNEY, Australia – 16 October 2023 – CSL Limited will today hold its inaugural Capital Markets Day to brief investors on its strategies to deliver annual double-digit earnings growth underpinning a steady improvement in return on invested capital (ROIC)[1] .

“CSL has leading positions in growing global markets with significant unmet need. Our three business units – CSL Behring, CSL Seqirus and CSL Vifor – are supported by best-in-class products and an innovative pipeline focused on new therapies and new indications. Our embedded know-how in scaled manufacturing platforms is driving efficiencies, yield improvements and productivity. By serving significant unmet patient needs and adding value to healthcare systems, we can deliver sustainable and profitable growth to support more innovation and research, and generate returns for our shareholders,” said Dr Paul McKenzie, CSL’s Chief Executive Officer and Managing Director.

Strategic highlights:

CSL’s market-leading plasma-based therapies, influenza vaccines and iron provide opportunities in growing global markets with significant unmet patient need, driven by innovation.
Demand for immunoglobulin (Ig) remains strong, presenting substantial growth prospects.
CSL Behring has a clear pathway to pre-COVID gross margins by optimising its donor payments, introducing new plasma collections technology and maximising Ig yield manufacturing.
CSL Seqirus is well positioned to outpace broader market growth through its differentiated innovation portfolio and continued investment in scalable manufacturing technologies.
CSL Vifor will continue to grow its leading iron franchise through market expansion and life cycle management.
By combining the expertise and product offering from CSL Behring and CSL Vifor, CSL is well-positioned to translate the World Health Organisation guidelines for Patient Blood Management to improve patient outcomes and minimise healthcare costs.
CSL has a range of R&D programmes nearing trial conclusion, which if successful and approved, will deliver additional growth.
CSL’s advances in digital and artificial intelligence technologies help reduce the time to collect plasma, discover new compounds, and conduct clinical trials.

CSL reaffirms guidance for FY24 with revenue growth of 9-11 per cent at constant currency and NPATA growth of 13-17 per cent at constant currency.

FURTHER INFORMATION

Additional details about CSL’s Capital Markets Day can be found on CSL’s website www.csl.com A glossary of medical terms can also be found on the website.

==> picture [63 x 36] intentionally omitted <==

For further information, please contact:

Jimmy Baker Communications CSL Limited P: +61 450 909 211 E: [email protected]

1 ROIC is expected to modestly soften in FY24, driven by the timing mismatch between the raising of funds to acquire Vifor Pharma and the payment of consideration.

AI assistant

CSL Ltd. — Investor Presentation 2023

17854_rns_2023-10-15_51dd0911-d845-4f6c-b1f0-59b926625014.pdf

CSL Capital Markets Day

For further information, please contact:

CSL Limited Capital Markets Day

IMPORTANT NOTICE AND DISCLAIMER

TRADEMARKS

Agenda

Strategic Overview

Leading Positions in Large, Growing Markets

Global #1

Global #2

Positioned for Annual Double-Digit Earnings Growth

Robust R&D Portfolio

Yield & capacity expansion

Disciplined capital allocation for growth

Strategic Focus Areas

Management Team

Andy Schmeltz

Joy Linton

Stephen Marlow

Mark Hill

Hervé Gisserot

Elizabeth Walker

Bill Mezzanotte

Kate Priestman

Ken Lim

Greg Boss

CSL Seqirus

CSL Seqirus growth linked directly to differentiation strategy and core capabilities

1. CONTINUED GROWTH IN INFLUENZA

2. BROADEN OUR PANDEMIC BUSINESS

Influenza still has significant unmet need, particularly in paediatric and older adult populations

Seasonal Influenza Burden

In influenza, Seqirus will grow the market through differentiation despite lower immunisation rates

Historic Trend (US)

Expectations

CSL Seqirus focused on continuous innovation to reduce the burden of influenza

sa-mRNA technology differentiates

Differentiators of sa-mRNA Technology

Accelerating to market

Key Takeaways

CSL Vifor

FY23 – a solid result with 11 months contribution[1]

~14% revenue growth[2] EPS accretive

Integration and cost synergies on track

CSL Vifor’s strategic framework will set the foundations to drive sustainable, profitable growth

Iron market: Unique conditions enabling us to drive long-term value

Iron market: Unique conditions enabling us to drive long-term value

Relentless focus on Ferinject[®] / Injectafer[®] growth

SIGNIFICANT UNTAPPED MARKET POTENTIAL

Patient Blood Management addresses a global health issue

Repeated Demonstrations of Patient & Health System Benefits when PBM is fully implemented

Benefits for patients

Countries calling on PBM implementation leading to addressable market of $4-5B across range of specialties

CSL is uniquely positioned in PBM to translate evidencebased medicine into evidence-based practice ​

Realising the market opportunity through integrated Go to Market operating model

Strengthen renal disease position along the full spectrum of kidney disease

CSL Vifor key value catalysts will drive growth into the medium - long term

Near-term

Mid-term

Cost Synergies

Indications / Geographic expansion

Thank You / Questions

CSL Behring

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

CSL Behring: Driving Sustainable, Profitable Growth

Working together from Donor to Patient

CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient

Snapshot of CSL Plasma’s Industry-Leading Collection Network

Global Plasma Collections Back on Track

Leading the Way in Plasma Growth & Efficiency

Multiple Levers to Support Collections Growth, Enabled by Digital Transformation

Clear Path to Driving Cost Per Litre (CPL) Efficiencies

COVID disruption led to

1 - 3 YEARS

2 - 4 Years

U.S. FDA Nomogram: Important Lever to Optimize Donations and Drive Plasma Yield

Benefits of Rika Plasma Donation System

CSL Ltd. Investor Presentation 2023

CSL is uniquely positioned in PBM to translate evidencebased medicine into evidence-based practice